CytomX Therapeutics (CTMX) Revenue (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Revenue data on file, last reported at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 79.85% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $35.5 million (down 75.91% YoY), and the FY2025 full-year result was $76.2 million, down 44.82% from the prior year.
• Revenue for Q1 2026 stood at $10.3 million, up from $663000.0 in the prior quarter.
• Across five years, Revenue topped out at $50.9 million in Q1 2025 and bottomed at $663000.0 in Q4 2025.
• The 5-year median for Revenue is $23.5 million (2023), against an average of $22.3 million.
• The widest annual swing landed in 2023, when Revenue jumped 159.94%; it then plunged 98.26% in 2025.
• A 5-year view of Revenue shows it stood at $20.1 million in 2022, then surged by 32.22% to $26.6 million in 2023, then soared by 43.17% to $38.1 million in 2024, then slumped by 98.26% to $663000.0 in 2025, then soared by 1447.21% to $10.3 million in 2026.
• The last three Revenue figures came in at $10.3 million (Q1 2026), $663000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.

Peer Comparison